Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.
Gonzague JourdainNicole Ngo-Giang-HuongLinda HarrisonLuc DeckerWoottichai KhamduangCamlin TierneyNicolas SalvadoriTim R CresseyWasna SirirungsiJullapong AchalapongPrapap YuthavisuthiPrateep KanjanavikaiOrada P Na AyudhayaThitiporn SiriwachirachaiSinart PrommasPrapan SabsanongAram LimtrakulSupang VaradisaiChaiwat PutiyanunPornnapa SuriyachaiPrateung LiampongsabuddhiSuraphan SangsawangWanmanee MatanasarawutSudanee BuranabanjasateanPichit PuernngooluermChureeratana BowonwatanuwongThanyawee PuthanakitVirat KlinbuayaemSatawat ThongsawatSombat ThanprasertsukGeorge K SiberryDiane H WattsNahida ChakhtouraTrudy V MurphyNoele P NelsonRaymond T ChungStanislas PolNantasak ChotivanichPublished in: The New England journal of medicine (2018)
In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT01745822 .).